Article info

Download PDFPDF
Systematic review
Very-low-strength evidence suggests that combining ezetimibe or fibrate with statins is no more effective than high-dose statin monotherapy for reducing all-cause mortality
  1. Correspondence to Professor Alexander Tenenbaum
    Cardiac Rehabilitation Institute, Chaim Sheba Medical Center, Tel-Hashomer 52621, Israel; altenen{at}post.tau.ac.il
View Full Text

Citation

Tenenbaum A, Fisman EZ
Very-low-strength evidence suggests that combining ezetimibe or fibrate with statins is no more effective than high-dose statin monotherapy for reducing all-cause mortality

Publication history

  • First published May 1, 2010.
Online issue publication 
May 01, 2010

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.